Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing
Obesogenic medication use is common in ESKD patients-particularly those with obesity-and is associated with lower listing likelihood. Whenever possible, non-obesogenic alternatives should be chosen for ESKD patients attempting weight loss to achieve transplant listing.
Authors
- Mara McAdams‐DeMarco (ORCID: https://orcid.org/0000-0003-3013-925X)
- Holly F. Lofton (ORCID: https://orcid.org/0000-0002-3403-882X)
- Akash Gujral (ORCID: https://orcid.org/0000-0003-4250-9086)
- Dorry Lidor Segev (ORCID: https://orcid.org/0000-0002-1924-4801)
- Sunjae Bae (ORCID: https://orcid.org/0000-0003-0098-8816)
- Yiting Li (ORCID: https://orcid.org/0000-0001-6279-5740)
- Babak John Orandi (ORCID: https://orcid.org/0000-0001-6026-7135)
- Bonnie E. Lonze (ORCID: https://orcid.org/0000-0002-0973-1657)
- Christine J. Ren‐Fielding (ORCID: https://orcid.org/0000-0002-2125-5382)
- Timur Seckin
Institutions
- New York University (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1111/ctr.15414
- Citations
- 2
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.90
Funders
- Eli Lilly and Company
- AstraZeneca
- CSL Behring
- Jazz Pharmaceuticals
- Novavax
- CareDx
- Novo Nordisk
- National Institutes of Health
- National Institute on Aging
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases